Brief: Aptose Reports Tuspetinib Improves Standard Of Care Treatment Across Diverse Populations Of Diagnosed AML In Trial
18/08/2025 15:15
Aug 18 (Reuters) - Aptose Biosciences Inc APS.TO: APTOSE REPORTS EARLY DATA DEMONSTRATING TUSPETINIB IMPROVES STANDARD OF CARE TREATMENT ACROSS DIVERSE POPULATIONS OF NEWLY DIAGNOSED AML IN PHASE 1/2 TUSCANY TRIAL APTOSE BIOSCIENCES INC - TUS ADDED TO VEN+AZA SHOWS 100% CR/CRH AT 80 MG AND 120 MG APTOSE BIOSCIENCES INC - TUS ADDED TO VEN+AZA IMPROVES MRD-NEGATIVITY TO 78% AMONG RESPONDERS APTOSE BIOSCIENCES INC - BROAD SPECTRUM ACTIVITY AND SAFETY AT 120 MG DOSE Source text: ID:nGNX5TmZMy Further company coverage: APS.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting